Combs Andrew
Chief Chemistry Officer | EVP, Head Of Chemistry
1 company
Insider Signal Score
56
GoodTrades Analyzed
5
12M Win Rate
60.0%
Avg 3M Return
-27.1%
Avg 12M Return
+25.2%
Combs Andrew is a Chief Chemistry Officer at Prelude Therapeutics Inc. Recent SEC Form 4 filings include 6 buys and 0 sells.
Estimated insider holdings value: $2.2M based on current market prices.
Holdings by Company
PRLDMar 25, 2025
Current Shares480.1K
Value$2.18M
Net Activity+172.1K
Bought: 172.1KSold: 0
Transaction History
Showing 4 filings
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2025 | PRLD Prelude Therapeutics Inc | Chief Chemistry Officer | Buy | 100,000 | $0.69 | $69,250.00 | +26.3% | +20.8% | +368.8% | |
| Dec 23, 2024 | PRLD Prelude Therapeutics Inc | Chief Chemistry Officer | Buy | 63,075 | $1.36 | $85,538.25 | +10.0% | -41.9% | +76.6% | |
| Dec 14, 2021 | PRLD Prelude Therapeutics Inc | EVP, Head Of Chemistry | Buy | 8,000 | $11.86 | $94,880.00 | +1.5% | -34.8% | -56.3% | |
| Sep 29, 2020 | PRLD Prelude Therapeutics Inc | EVP, Head Of Chemistry | Buy | 1,000 | $19.00 | $19,000.00 | +0.4% | - | - |